Full Press Release Details
Xenetic Biosciences Reports 2017 Second Quarter
Financial Results and Provides Business Update
MA - (August 15, 2017) - Xenetic Biosciences, Inc. (NASDAQ:
XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery,
research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited
financial results for the quarter ended June 30, 2017.
Xenetic also provided
an update to its corporate progress as well as clinical and regulatory status and anticipated milestones for the Company's lead
product candidate, XBIO-101 (sodium cridanimod), a small-molecule immunomodulator and interferon inducer which, in preliminary
studies, has been shown to increase progesterone receptor ("PrR") expression in endometrial tumor tissue, and an update
on its proprietary PolyXen platform technology.
quarter was marked by the advancement of our flagship program, XBIO-101, into our Phase 2 program for the treatment of endometrial
cancer, along with the important data we received from Shire's Phase 1/2 study of SHP656, which utilized our PolyXen platform
technology. While this study did not meet its primary endpoint and Shire has subsequently stated the program has been discontinued,
key findings from the study specific to our PolyXen platform technology, provide further validation that it has the potential to
improve the clinical utility of protein and peptide drugs," stated M. Scott Maguire, Xenetic's CEO.
In the second quarter
of 2017, the Company commenced patient enrollment for its Phase 2 clinical study of XBIO-101 in conjunction with progestin therapy
for the treatment of endometrial cancer. The study targets a population of patients who have either failed progestin monotherapy
or who have been identified as having progesterone receptor negative ("PrR-") tumors.
The primary objective
of the open-label, multi-center, single-arm, two-period Phase 2 study is to assess the antitumor activity of XBIO-101 in conjunction
with progestin therapy as measured by Overall Disease Control Rate in women with recurrent or persistent endometrial carcinoma
not amenable to surgical treatment or radiotherapy who have either failed progestin monotherapy or who have been identified as
PrR-. Secondary objectives include assessments of efficacy and safety/tolerability parameters.
The study is expected
to enroll up to 72 women with recurrent or persistent endometrial cancer not amenable to surgical treatment or radiotherapy but
suitable to be treated with progestins. All subjects determined to be PrR- at screening, as well as those subjects who experience
disease progression after at least 4 weeks of progestin monotherapy, will receive XBIO-101 in combination with continued progestin
treatment. Subjects will receive treatment until disease progression as defined according to RECIST 1.1 criteria.
Xenetic has also filed
a protocol under its existing Investigational New Drug application to expand the development of XBIO-101 into a biomarker study
related to the treatment of triple negative breast cancer.
May 2017, the Company, along with its strategic collaborator, Shire plc (LSE: SHP, NASDAQ: SHPG), announced data from Shire's
Phase 1/2 program of SHP656, its PSA-Recombinant Factor VIII ("rFVIII"),
which was being developed as a long-acting therapeutic for the treatment of hemophilia A, utilizing Xenetic's PolyXen platform
technology to conjugate polysialic acid to therapeutic blood-clotting factors. Despite not achieving the principal objective of
once-weekly dosing in this Phase 1/2 study, the Company's PolyXen technology demonstrated that it works as a platform to
successfully extend the circulating half-life of rFVIII with no drug-related serious adverse events reported to date. Including
the Company's own studies with a polysialylated erythropoietin ("PSA-EPO", "ErepoXen ") candidate,
this is the second instance in which PolyXen platform technology has been demonstrated, in a human clinical trial setting, to confer
extended half-life to a biotherapeutic, while maintaining pharmacological activity and a favorable safety and tolerability profile. Moving
forward, Xenetic believes data from Shire's SHP656 program, although discontinued, continues to support the broad utility
of its proprietary PolyXen technology platform, and expects the growing body of data from this platform will enable the Company
to build a pipeline of partnerships utilizing this proven technology.
on driving forward with our strategy, including the continued advancement of our lead product candidate XBIO-101, as well as leveraging
our proprietary PolyXen platform technology with the goal of building shareholder value in both the near and long-term,"
concluded Mr. Maguire.
Summary of Financial Results for Second
Net loss for the three
months ended June 30, 2017, was $2.9 million compared to a net loss of approximately $47.8 million for the same period in 2016.
The decrease in net loss was primarily due to a decrease of in-process research and development expense, as well as a decrease
in share-based compensation expense related to warrants previously issued in 2016. These decreases were offset by an increase in
general operating costs and costs related to the initiation of our XBIO-101 Phase 2 clinical study.
the quarter with approximately $2.3 million of cash.
About Xenetic Biosciences
Xenetic Biosciences,
Inc. is a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic
drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug development platforms include PolyXen, which enables next-generation
biologic drugs by improving their half-life and other pharmacological properties. Xenetic's lead investigational product candidates
include oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer, and a
polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease.
Xenetic is party to an agreement with Baxalta
US Inc. and Baxalta AB (wholly owned subsidiaries of Shire plc) covering the development of a novel series of polysialylated blood
coagulation factors. This collaboration relies on Xenetic's PolyXen technology to conjugate polysialic acid ("PSA")
to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of
these biologic molecules. Shire is a significant stockholder of the Company, having invested $10 million in the Company during
2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing
license to Xenetic's PSA patented and proprietary technology in combination with Shire's proprietary molecules designed for the
treatment of blood and bleeding disorders. The first program under this agreement was a next generation Factor VIII, and this program
was terminated by Shire following a Phase 1/2 clinical trial. Xenetic and Shire are currently exploring whether to engage in further
development of other blood coagulation factors. Additionally, Xenetic has previously received strategic investments from OPKO Health
(Nasdaq: OPK), Serum Institute of India Limited and PJSC Pharmsynthez.
Xenetic is also developing a broad pipeline
of clinical candidates for next-generation biologics and novel oncology therapeutics in a number of orphan disease indications.
For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, Facebook and Google+.
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained
in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of
the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding the Company's ability to develop and customize the Company's
PolyXen platform technology to improve the clinical utility of protein and peptide drugs; the Company's anticipated
corporate development strategies and pursuit of current and future collaborations to co-develop new product candidates; its ability
to add new programs to its pipeline and expand the development of its current product candidates into new indications; the initiation,
timing, progress, enrollment and reporting of results of its preclinical programs and clinical trials; the Company's potential
for future growth and creation of shareholder value; and the Company's liquidity and ability to fund its future operations;.
Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties.
Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking
statements. These risks and uncertainties include those described in the "Risk Factors" section of the Company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and filed with the Securities and Exchange Commission on
March 31, 2017, and subsequent reports that it may file with the Securities and Exchange Commission. In addition, forward-looking
statements may also be adversely affected by general market factors, competitive product development, product availability, federal
and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues
that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking
statements, except as required by law.
Jenene Thomas Communications, LLC.
Source: Xenetic Biosciences,